PARP inhibitors
NGS Tumor Testing Gaps Persist in Metastatic Prostate, Urothelial Cancers
A retrospective health record analysis revealed an inconsistent rise in rates of next-generation sequencing testing in metastatic prostate cancer and advanced urothelial cancer.
Angle Inks Assay Development Deal with AstraZeneca
The company is working to tailor its existing circulating tumor cell DNA damage response assay for use in pharmaceutical R&D.
Failed Trial Suggests Circulating Tumor DNA Monitoring Not as Universally Applicable as Hoped
Premium
Investigators stressed that their results don't mean that ctDNA monitoring shouldn't be pursued in advanced cancer settings but that they offer a cautionary tale.
Investigators affiliated with Friends of Cancer Research reported progress in assay concordance projects and discussed evolving aspects of lab test regulation at an update meeting.
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.